Sibutramine and Rimonabant

Sibutramine and Rimonabant are both anorexigenic drugs, designed for anti-obesity treatment. Due to potential risk of severe side effects, these drugs were withdrawn from pharmacological markets of most developed countries.

Sibutramine (Yeduc) psychostimulant was approved in 1997. At this moment, it is impossible to buy Sibutramine and its generic drugs at the U.S. and EU pharmacies. Rimonabant has got no FDA approval and has never been sold within the USA.

Both medications can normalize the eating behavior, increasing satiety and reducing the energy input by reducing the amount of consumed food.

Just as most prescription appetite suppressants, stimulating the brain, Sibutramine and Rimonabant are contraindicated in such pathologies and diseases, as:

  • Renal and hepatic insufficiency
  • Hypersensitivity to the drug
  • Anorexia nervosa or bulimia nervosa
  • Hereditary heart disease
  • Mental diseases
  • Stroke
  • Coronary artery disease
  • Heart failure
  • Organic causes of obesity.

Many patients with extra weight or obesity had to stop using Sibutramine and Rimonabant drugs due to side effects. The most common side effects are:

  • Headache and dizziness
  • Difficult falling asleep and sleep maintenance
  • Dryness and unpleasant taste in the mouth
  • High blood pressure
  • Anxiety and worry.